SCHEMBL23533172

SCHEMBL23533172

COc1ccc(CN2CCCC[C@H]2COc2ccc3c(c2)CN(C2CCC(=O)NC2=O)C3=O)cc1OC

nearest known ligand 0.79

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ WIZ O95785 6/20 0.79
▸ IKZF2 Q9UKS7 8/20 0.49
▸ MAPK1 P28482 1/20 0.47
▸ CRBN Q96SW2 2/20 0.45
▸ IKZF1 Q13422 2/20 0.44
▸ TNF P01375 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23533174 1.00 WIZ (0.79) WIZIKZF2MAPK1CRBNIKZF1
SCHEMBL23532845 0.94 WIZ (0.77) WIZIKZF2CRBNIKZF1
SCHEMBL23532848 0.94 WIZ (0.77) WIZIKZF2CRBNIKZF1
SCHEMBL27130491 0.94 WIZ (0.77) WIZIKZF2CRBNIKZF1
SCHEMBL23533021 0.94 WIZ (0.77) WIZIKZF2CRBNIKZF1
SCHEMBL23532803 0.94 WIZ (0.76) WIZIKZF2CRBNIKZF1
SCHEMBL23532807 0.94 WIZ (0.76) WIZIKZF2CRBNIKZF1
SCHEMBL23533083 0.94 WIZ (0.76) WIZIKZF2CRBNIKZF1
SCHEMBL24761941 0.94 WIZ (0.76) WIZIKZF2CRBNIKZF1
SCHEMBL23532920 0.92 WIZ (0.74) WIZIKZF2CRBNIKZF1TNF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114828959-B 3- (5-methoxy-1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivative and application thereof 诺华股份有限公司 2024-04-02 — — CN claimed
EP-4076650-B1 3-(5-METHOXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2024-02-28 — — EP claimed
US-11566022-B2 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof NOVARTIS AG (CH) 2023-01-31 — — US claimed
US-20220402904-A1 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof NOVARTIS AG (CH) 2022-12-22 — — US claimed
CN-114828959-A 3- (5-methoxy-1-oxoisoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof 诺华股份有限公司 2022-07-29 — — CN claimed
WO-2021124172-A1 3-(5-METHOXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2021-06-24 — — WO claimed
CN-114828959-B 3- (5-methoxy-1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivative and application thereof 诺华股份有限公司 2024-04-02 — — CN disclosed
US-11566022-B2 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof NOVARTIS AG (CH) 2023-01-31 — — US disclosed
US-20220402904-A1 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof NOVARTIS AG (CH) 2022-12-22 — — US disclosed
CN-114828959-A 3- (5-methoxy-1-oxoisoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof 诺华股份有限公司 2022-07-29 — — CN disclosed
WO-2021124172-A1 3-(5-METHOXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2021-06-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11566022-B2 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof HBZ, ZFX, HBG1 WIZ 6/4885IKZF2 7/4885MAPK1 4448/4885
US-20220402904-A1 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof HBZ, ZFX, HBG1 WIZ 6/4885IKZF2 7/4885MAPK1 4425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback